ATE297381T1 - Ether-muskarinantagonisten - Google Patents
Ether-muskarinantagonistenInfo
- Publication number
- ATE297381T1 ATE297381T1 AT97937152T AT97937152T ATE297381T1 AT E297381 T1 ATE297381 T1 AT E297381T1 AT 97937152 T AT97937152 T AT 97937152T AT 97937152 T AT97937152 T AT 97937152T AT E297381 T1 ATE297381 T1 AT E297381T1
- Authority
- AT
- Austria
- Prior art keywords
- optionally substituted
- alkyl
- formula
- antagonists
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70072296A | 1996-08-15 | 1996-08-15 | |
| PCT/US1997/013894 WO1998006697A1 (en) | 1996-08-15 | 1997-08-13 | Ether muscarinic antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE297381T1 true ATE297381T1 (de) | 2005-06-15 |
Family
ID=24814614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97937152T ATE297381T1 (de) | 1996-08-15 | 1997-08-13 | Ether-muskarinantagonisten |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0922029B1 (de) |
| JP (1) | JP3390179B2 (de) |
| KR (1) | KR20000029976A (de) |
| CN (1) | CN1155574C (de) |
| AT (1) | ATE297381T1 (de) |
| AU (1) | AU732096B2 (de) |
| BR (1) | BR9711061A (de) |
| CA (1) | CA2263167C (de) |
| CZ (1) | CZ43399A3 (de) |
| DE (1) | DE69733478T2 (de) |
| ES (1) | ES2241053T3 (de) |
| HU (1) | HUP9904363A3 (de) |
| IL (1) | IL128524A0 (de) |
| NO (1) | NO990671L (de) |
| NZ (1) | NZ334017A (de) |
| PL (1) | PL331536A1 (de) |
| SK (1) | SK20199A3 (de) |
| TR (1) | TR199900314T2 (de) |
| WO (1) | WO1998006697A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| CN1303376A (zh) * | 1998-03-31 | 2001-07-11 | 阿卡蒂亚药品公司 | 对毒蕈碱性受体具有活性的化合物 |
| AU779354B2 (en) | 1998-12-23 | 2005-01-20 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
| US6387930B1 (en) | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| US6635646B1 (en) | 1999-05-04 | 2003-10-21 | Schering Corporation | Pegylated interferon alfa-CCR5 antagonist combination HIV therapy |
| WO2000066559A1 (en) * | 1999-05-04 | 2000-11-09 | Schering Corporation | Piperidine derivatives useful as ccr5 antagonists |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
| CN1329382C (zh) | 2001-05-11 | 2007-08-01 | 比奥维特罗姆股份公司 | 治疗肥胖、ⅱ型糖尿病和cns－疾病的芳基磺酰胺化合物 |
| WO2003004487A1 (en) | 2001-07-02 | 2003-01-16 | Astrazeneca Ab | Piperidine derivatives useful as modulators of chemokine receptor activity |
| GB0120461D0 (en) | 2001-08-22 | 2001-10-17 | Astrazeneca Ab | Novel compounds |
| GB0122503D0 (en) | 2001-09-18 | 2001-11-07 | Astrazeneca Ab | Chemical compounds |
| KR100579813B1 (ko) * | 2001-10-16 | 2006-05-12 | 주식회사 에스티씨나라 | 피페리딘 유도체, 이의 제조방법 및 이를 포함하는 치매치료용 약학적 조성물 |
| DE10201550A1 (de) * | 2002-01-17 | 2003-07-31 | Merck Patent Gmbh | Phenoxy-Piperidine |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| AU2003236364C1 (en) | 2002-06-14 | 2009-12-24 | Toyama Chemical Co., Ltd. | Medicinal compositions improving brain function and method for improving brain function |
| SE0202838D0 (sv) * | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| SE0302956D0 (sv) * | 2003-11-07 | 2003-11-07 | Astrazeneca Ab | Chemical compounds |
| TW200722419A (en) * | 2005-05-27 | 2007-06-16 | Astrazeneca Ab | Chemical compounds |
| US20080200505A1 (en) * | 2005-05-27 | 2008-08-21 | Astrazeneca Ab | Piperidines for the Treatment of Chemokine Mediated Diseases |
| KR20080037655A (ko) | 2005-07-21 | 2008-04-30 | 아스트라제네카 아베 | 신규 피페리딘 유도체 |
| DE102008008838A1 (de) | 2008-02-13 | 2009-08-20 | Bayer Healthcare Ag | Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| IN2012DN06631A (de) | 2010-02-16 | 2015-10-23 | Pfizer | |
| EP3757102A1 (de) | 2016-03-17 | 2020-12-30 | F. Hoffmann-La Roche AG | 5-ethyl-4-methyl-pyrazole-3-carboxamid-derivat mit wirkung als taar agonist |
| WO2018112843A1 (en) * | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112840A1 (en) * | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| ATE256110T1 (de) * | 1995-09-15 | 2003-12-15 | Neurosearch As | Piperindinverbindungen als calcium-kanal-blocker |
-
1997
- 1997-08-13 JP JP50985498A patent/JP3390179B2/ja not_active Expired - Fee Related
- 1997-08-13 WO PCT/US1997/013894 patent/WO1998006697A1/en active IP Right Grant
- 1997-08-13 AU AU39732/97A patent/AU732096B2/en not_active Ceased
- 1997-08-13 TR TR1999/00314T patent/TR199900314T2/xx unknown
- 1997-08-13 CZ CZ99433A patent/CZ43399A3/cs unknown
- 1997-08-13 IL IL12852497A patent/IL128524A0/xx unknown
- 1997-08-13 ES ES97937152T patent/ES2241053T3/es not_active Expired - Lifetime
- 1997-08-13 NZ NZ334017A patent/NZ334017A/xx unknown
- 1997-08-13 EP EP97937152A patent/EP0922029B1/de not_active Expired - Lifetime
- 1997-08-13 KR KR1019997001227A patent/KR20000029976A/ko not_active Application Discontinuation
- 1997-08-13 HU HU9904363A patent/HUP9904363A3/hu unknown
- 1997-08-13 AT AT97937152T patent/ATE297381T1/de not_active IP Right Cessation
- 1997-08-13 BR BR9711061A patent/BR9711061A/pt unknown
- 1997-08-13 CA CA002263167A patent/CA2263167C/en not_active Expired - Fee Related
- 1997-08-13 SK SK201-99A patent/SK20199A3/sk unknown
- 1997-08-13 DE DE69733478T patent/DE69733478T2/de not_active Expired - Fee Related
- 1997-08-13 PL PL97331536A patent/PL331536A1/xx unknown
- 1997-08-13 CN CNB971985588A patent/CN1155574C/zh not_active Expired - Fee Related
-
1999
- 1999-02-12 NO NO990671A patent/NO990671L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9711061A (pt) | 1999-08-17 |
| CN1155574C (zh) | 2004-06-30 |
| IL128524A0 (en) | 2000-01-31 |
| CN1232453A (zh) | 1999-10-20 |
| DE69733478T2 (de) | 2005-11-03 |
| NO990671L (no) | 1999-04-15 |
| WO1998006697A1 (en) | 1998-02-19 |
| CA2263167A1 (en) | 1998-02-19 |
| NO990671D0 (no) | 1999-02-12 |
| HUP9904363A3 (en) | 2000-12-28 |
| JP2000500786A (ja) | 2000-01-25 |
| CA2263167C (en) | 2006-02-14 |
| HUP9904363A2 (hu) | 2000-11-28 |
| PL331536A1 (en) | 1999-07-19 |
| TR199900314T2 (xx) | 1999-05-21 |
| KR20000029976A (ko) | 2000-05-25 |
| EP0922029B1 (de) | 2005-06-08 |
| ES2241053T3 (es) | 2005-10-16 |
| AU3973297A (en) | 1998-03-06 |
| NZ334017A (en) | 2000-04-28 |
| JP3390179B2 (ja) | 2003-03-24 |
| AU732096B2 (en) | 2001-04-12 |
| EP0922029A1 (de) | 1999-06-16 |
| CZ43399A3 (cs) | 1999-07-14 |
| DE69733478D1 (de) | 2005-07-14 |
| SK20199A3 (en) | 2000-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE297381T1 (de) | Ether-muskarinantagonisten | |
| MY133992A (en) | Muscarinic antagonists | |
| EA200100553A1 (ru) | Замещенные бициклические производные, полезные в качестве противораковых агентов | |
| IL117149A0 (en) | Muscarinic antagonists | |
| ATE224884T1 (de) | Muscarin-antagonisten | |
| NZ333801A (en) | Piperidine and piperazine derivatives and their use as muscarinic antagonists | |
| PT912515E (pt) | Piperidinas 1,4-di-substituidas como antagonistas muscarinicos | |
| PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| PL361282A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| ES2087038A1 (es) | Nuevas piperidinas con actividad antagonista del paf. | |
| MY133445A (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives | |
| SE9703377D0 (sv) | New compounds | |
| HUT57773A (en) | Process for produicng n-(aminocarbonyl)-carbamates related to physostigmine, as well as pharmaceutical compositions comprising such compounds | |
| NZ543068A (en) | Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
| DK0556813T3 (da) | Amfotere tricykliske forbindelser som antihistaminske og antiallergiske midler | |
| RU2003105827A (ru) | Средства против слабоумия, содержащие производные 2-арил-8-оксодигидропурина, в качестве активного ингредиента | |
| ECSP003505A (es) | Derivados de 4-fenil- pirimidina | |
| ECSP003642A (es) | Antagonistas muscarinicos | |
| ECSP972216A (es) | Antagonistas muscarinicos | |
| CA2180660A1 (en) | Novel piperidine derivatives with paf antagonist activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |